Shots:

• AstraZeneca has completed its agreement with Allergan to recover the global rights to brazikumab (formerly MEDI2070). Both the companies have terminated their 2016 agreement and all rights to brazikumab- now returned to AstraZeneca
• Allergan to fund up to an agreed amount- estimated to be the total costs expected to be incurred by AstraZeneca until completion of the development of brazikumab for CD and UC- including the development of a CDx
• Pursuant to 2012 collaboration with Amgen- AstraZeneca will grant royalties on sales of brazikumab- if approved and launched. Brazikumab is mAb targeting IL23 and is in development for CD and UC with a companion biomarker

Click here to­ read full press release/ article 

Ref: AstraZeneca | Image: AstraZeneca